Investigator Registration and Financial Disclosure for Investigational Trials in Cancer Treatment (NCI)
Existing collection in use without an OMB Control Number
No
Regular
Improperly submitted
09/14/2009
08/19/2009
Package must be submitted with burden attributed to "Change Due to Potential Violation of the PRA."
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
36 Months From Approved
0
0
0
0
0
0
0
0
0
The FDA holds the NCI responsible, as a sponsor of investigational drug trials, for the collection of information about the clinical investigators who participate in these trials. The information collected is used to identify qualified investigators and to facilitate the submission and distribution of important information relative to the investigational drug and the response of the patient to that drug. Investigators are physicians who specialize in the treatment of patients with cancer.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.